SEELOS THERAPEUTICS INC (SEEL) Stock Price & Overview
NASDAQ:SEEL • US81577F3073
Current stock price
The current stock price of SEEL is 1.28 USD. Today SEEL is down by -47.76%. In the past month the price decreased by -64.44%. In the past year, price decreased by -99.83%.
SEEL Key Statistics
- Market Cap
- 563.2K
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -45.32
- Dividend Yield
- N/A
SEEL Stock Performance
SEEL Stock Chart
SEEL Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to SEEL. When comparing the yearly performance of all stocks, SEEL is a bad performer in the overall market: 99.8% of all stocks are doing better.
SEEL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SEEL. SEEL may be in some trouble as it scores bad on both profitability and health.
SEEL Earnings
SEEL Forecast & Estimates
7 analysts have analysed SEEL and the average price target is 122.4 USD. This implies a price increase of 9462.5% is expected in the next year compared to the current price of 1.28.
For the next year, analysts expect an EPS growth of 97.05% and a revenue growth -81.25% for SEEL
SEEL Groups
Sector & Classification
SEEL Financial Highlights
Over the last trailing twelve months SEEL reported a non-GAAP Earnings per Share(EPS) of -45.32. The EPS decreased by -318.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 203.13% | ||
| ROA | 171.82% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SEEL Ownership
SEEL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.38 | 871.596B | ||
| JNJ | JOHNSON & JOHNSON | 18.93 | 578.307B | ||
| MRK | MERCK & CO. INC. | 23.56 | 296.588B | ||
| PFE | PFIZER INC | 9.07 | 154.211B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.17 | 118.584B | ||
| ZTS | ZOETIS INC | 17.12 | 51.124B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.45 | 28.162B | ||
| VTRS | VIATRIS INC | 5.58 | 16.197B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.91 | 11.987B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.421B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.45B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.08B | ||
| CORT | CORCEPT THERAPEUTICS INC | 80.5 | 4.646B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SEEL
Company Profile
Seelos Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in New York City, New York and currently employs 10 full-time employees. Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The firm operates under one segment which develops pharmaceutical products. The firm's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The firm's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.
Company Info
IPO: 1993-10-27
SEELOS THERAPEUTICS INC
300 Park Avenue, 2nd Floor
New York City NEW YORK 10022 US
CEO: Raj Mehra
Employees: 8
Phone: 16462932100
SEELOS THERAPEUTICS INC / SEEL FAQ
What does SEELOS THERAPEUTICS INC do?
Seelos Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in New York City, New York and currently employs 10 full-time employees. Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The firm operates under one segment which develops pharmaceutical products. The firm's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The firm's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.
Can you provide the latest stock price for SEELOS THERAPEUTICS INC?
The current stock price of SEEL is 1.28 USD. The price decreased by -47.76% in the last trading session.
What is the dividend status of SEELOS THERAPEUTICS INC?
SEEL does not pay a dividend.
What is the ChartMill technical and fundamental rating of SEEL stock?
SEEL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is SEELOS THERAPEUTICS INC (SEEL) stock traded?
SEEL stock is listed on the Nasdaq exchange.
What is the GICS sector and industry of SEEL stock?
SEELOS THERAPEUTICS INC (SEEL) operates in the Health Care sector and the Pharmaceuticals industry.
What is the Price/Earnings (PE) ratio of SEELOS THERAPEUTICS INC (SEEL)?
SEELOS THERAPEUTICS INC (SEEL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-45.32).